Randomized Phase II Study of Azacitidine in Combination with Lenalidomide vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
The purpose of this study is to compare the effects, good and/or bad on a participant’s MDS or CMML, of adding either the drug lenalidomide or the drug vorinostat to the standard treatment drug azacitidine. Participants in this study have been diagnosed with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). This means that their bone marrow does not create enough of at least one type of blood cell that the body needs. In this study, participants will be on one of the following treatment arms: azacitidine alone, azacitidine and lenalidomide or azacitidine and vorinostat.
Back to Clinical Trials list